Chronic hepatitis C: future treatment

The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to genotype 1 (GT-1) patients. The development of second-wave and second-generation PIs yields higher antiviral potency through plurigenotypic activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wendt, Astrid, Adhoute, Xavier, Castellani, Paul, Oules, Valerie, Ansaldi, Christelle, Benali, Souad, Bourlière, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891518/
https://www.ncbi.nlm.nih.gov/pubmed/24470777
http://dx.doi.org/10.2147/CPAA.S30338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891518/
https://www.ncbi.nlm.nih.gov/pubmed/24470777
http://dx.doi.org/10.2147/CPAA.S30338

Ejemplares similares